Scott Gottlieb, Commissioner of the U.S. Food and Drug Administration, tweeted on June 22: “We have advised Perrigo that it failed to comply with #FDA postmarketing requirements for a study intended to determine the cardiovascular effects of testosterone replacement therapy product, Testosterone Gel, by the agreed upon deadline.” With the tweet, he attached a link to a letter sent to Perrigo that was posted to the FDA website.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.